Cezanne Kooij

Ms. Cezanne Kooij

BSc
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CKCezanne Kooij
Cezanne Kooij
CHCaroline Hulsker
Caroline Hulsker
MKMariette Kranendonk
Mariette Kranendonk
JZJózsef Zsiros
József Zsiros
ALAnnemieke S. Littooij
Annemieke S. Littooij
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
Objective: The purpose of this review is to evaluate the outcomes of testis sparing surgery (TSS) and to investigate under which circumstances TSS can be considered a safe treatment option in pediatric patients with testicular tumors. Methods: A database search was performed in Cochrane, Pubmed, and Embase for studies that focused on TSS as treatment for testicular tumors in the pediatric population, excluding reviews and single case reports. Results: Twenty studies, describing the surgical treatment of 777 patients with testicular tumors, were included in the analysis. The majority of pediatric patients with benign germ cell tumors (GCTs) (mean age: 3.7 years) and sex cord-stromal tumors (SCSTs) (mean age: 6.6 years) were treated with TSS, 61.9% and 61.2%, respectively. No cases of testicular atrophy occurred. Four of the benign GCTs, i.e., three teratomas and one epidermoid cyst, recurred. No cases of recurrence were reported in patients with SCSTs. Of the 243 malignant GCTs (mean age: 4.2 years), only one patient had TSS (0.4%). Conclusion: TSS is a safe treatment option for prepubertal patients less than 12 years of age with benign GCTs and low grade SCSTs.

5 January 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
ERElja A.E. Reijneveld
Elja A.E. Reijneveld
CKCezanne Kooij
Cezanne Kooij
JDJaap J. Dronkers
Jaap J. Dronkers
BKB. Feike Kingma
B. Feike Kingma
JSJoyce M.A. Stel
Joyce M.A. Stel
EAEdwin van Adrichem
Edwin van Adrichem
This study evaluates the course of physical fitness and nutritional status during curative therapy for esophageal cancer, after implementation of a prehabilitation program. Additionally, the impact of baseline physical fitness level and severe postoperative complications on the course of individual patients were explored. This multicenter, observational cohort study included patients with esophageal cancer following curative treatment. Prehabilitation, consisting of supervised exercise training and nutritional counseling was offered as standard care to patients after neoadjuvant therapy, prior to surgery. Primary outcome measures included change of exercise capacity, hand grip strength, self-reported physical functioning, Body Mass Index, and malnutrition risk from diagnosis to 2-6 months postoperatively. Analyses over time were performed using linear mixed models, and linear mixed regression models to investigate the impact of baseline level and severe postoperative complications. Hundred sixty-eight patients were included (mean age 65.9 ± 8.6 years; 78.0 % male). All parameters (except for malnutrition risk) showed a decline during neoadjuvant therapy (p < .05), an improvement during prehabilitation (p < .005) and a decline postoperatively (p < .001), with a high heterogeneity between patients. Change in the outcomes from baseline to postoperatively was not different for patients with or without a severe complication. Better baseline physical fitness and nutritional status were significantly associated with a greater decline postoperatively (p < .001). This study demonstrates a notable decline during neoadjuvant therapy, that fully recovers during prehabilitation, and a subsequent long lasting decline postoperatively. The heterogeneity in the course of physical fitness and nutritional status underlines the importance of individualized monitoring.

5 June 2025 in Digestive Surgery
Verified
Journal Article
Open access
CKCezanne Kooij
Cezanne Kooij
LGLucas Goense
Lucas Goense
BKB. Feike Kingma
B. Feike Kingma
RHRichard van Hillegersberg
Richard van Hillegersberg
JRJelle Ruurda
Jelle Ruurda
Background: Esophagectomy, the cornerstone in the multimodal treatment of esophageal cancer, has evolved from open surgery to minimally invasive esophagectomy (MIE) in recent decades. MIE reduces complications, facilitates faster recovery, and provides comparable or superior oncologic outcomes and survival rates compared to open surgery. Summary: Since the early 2000s, robot-assisted minimally invasive esophagectomy (RAMIE) has emerged, offering enhanced precision over MIE through features such as three-dimensional visualization, improved instrument dexterity, tremor filtration, and motion scaling. These innovations help overcome the challenges of MIE, particularly in the thoracic phase, where limited access and reduced instrument dexterity hamper the procedure. RAMIE is associated with lower complication rates, particularly pulmonary complications, improved recovery, and comparable oncological outcomes. Despite higher initial costs, its potential to reduce complications makes it financially comparable to other approaches. Moreover, mastering RAMIE requires navigating a significant learning curve, making collaboration and training vital. The integration of artificial intelligence and advancements in robotic platforms, including single-port systems, will broaden patient eligibility and improve outcomes. Key Messages: RAMIE has established itself as an integral part of modern surgical practice and will continue to evolve, driving further innovation. Collaboration and training are essential for refining techniques and ensuring safe and effective implementation.

8 September 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CKCezanne Kooij
Cezanne Kooij
AMAnnelies M.C. Mavinkurve-Groothuis
Annelies M.C. Mavinkurve-Groothuis
IHIdske C L Kremer Hovinga
Idske C L Kremer Hovinga
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
TRTuula Rinne
Tuula Rinne
ASAnnemarie A Verrijn Stuart
Annemarie A Verrijn Stuart
Objective The purpose of this study is to report development of a malignant testicular germ cell tumor (GCT) in two young adult males with Familial Male-limited Precocious Puberty (FMPP) due to (LHCGR) pathogenic variants in two families. Secondary, to study the possible relation between FMPP and testicular tumors and to investigate whether FMPP might predispose to development of malignant testicular tumors in adulthood a literature review is conducted. Methods Data on six cases in two families are obtained from the available medical records. In addition, a database search is performed in Cochrane, Pubmed and Embase for studies that report on a possible link between FMPP and testicular tumors. Results The characteristics of six males with FMPP based on activating luteinizing hormone receptor (LHCGR) germline pathogenic variants are described, as well as details of the testicular GCTs. Furthermore, literature review identified four more patients with signs of FMPP and a (precursor of a) testicular GCT in adolescence or adulthood (age 15 to 35 years). Additionally, twelve patients with signs of precocious puberty and, simultaneously, occurrence of a Leydig cell adenoma or Leydig cell hyperplasia are reported. Conclusion There is a strong suggestion that FMPP might increase the risk of development of testicular GCTs in early adulthood compared to the risk in the general population. Therefore, prolonged patient monitoring from mid-pubertal age onwards including instruction for self-examination and periodic testicular ultrasound investigation in patients with a germline LHCGR pathogenic variants might contribute to early detection and thus early treatment of testicular GCT.

29 November 2025 in British Journal of Surgery
Verified
Journal Article
Closed access
THTobias Hauge
Tobias Hauge
AHAram Abu Hejleh
Aram Abu Hejleh
Alberto AiolfiAlberto Aiolfi
Alberto Aiolfi
FBFelix Berlth
Felix Berlth
Luigi BonavinaLuigi Bonavina
Luigi Bonavina
WSWolfgang Schröder
Wolfgang Schröder
Background: Boerhaave syndrome is defined as a spontaneous perforation of the oesophagus. The mainstay of treatment is resuscitation of the patient, closure of the oesophageal defect, and drainage of perioesophageal and pleural fluid collections. Whether the optimal approach is endoscopic, surgical, or conservative management remains unknown and there are no clear guidelines. The aim of this multicentre retrospective cohort study was to evaluate current treatment strategies and outcomes for Boerhaave syndrome. Methods: A multicentre retrospective analysis of data from 23 participating European tertiary centres was performed. Patients with Boerhaave syndrome treated between January 2019 and December 2023 were eligible for inclusion. The primary endpoint was the length of ICU stay and secondary endpoints included in-hospital mortality, 90-day mortality, and the length of overall hospital stay. Results: In total, 216 patients were included; 151 were men (70%), the median age was 62 (22–95) years, and 81 (40%) were treated >24 h after the start of symptoms. Seventy (32%) patients were managed endoscopically (group I), 73 (34%) were managed surgically (group II), 67 (31%) were managed using a combination of endoscopy and surgery (group III), and 6 (3%) were managed using other methods (group IV). For patients in groups I–III: the median length of ICU stay was 8 (0–67) days, with no differences between the three groups (P = 0.105); the in-hospital mortality rate and 90-day mortality rate were both 12% (P = 0.490 and P = 0.637, respectively); and the median length of overall hospital stay was 27 (range 1–193) days, with the longest stays observed in patients who received combined treatment (P = 0.032). Conclusion: This study provides a comprehensive overview of the current treatment strategies and outcomes for patients with Boerhaave syndrome in Europe.

1 September 2025 in Diseases of the Esophagus
Verified
Journal Article
Open access
CKCezanne Kooij
Cezanne Kooij
LGLucas Goense
Lucas Goense
BKB Feike Kingma
B Feike Kingma
RBRobin B Den Boer
Robin B Den Boer
ESElles Steenhagen
Elles Steenhagen
RHRichard van Hillegersberg
Richard van Hillegersberg
Background: The optimal time to resume oral intake after esophagectomy remains debated, with practices varying across centers. Methods: This single-center, retrospective cohort study compared early and late oral feeding regimens after esophagectomy. Perioperative care was identical except for the feeding regimen. Early oral feeding began immediately post-surgery, while late oral feeding started on postoperative day 4 after swallow examination, with jejunostomy for early enteral tube feeding. Propensity score matching was used to reduce confounding. The primary outcome was overall survival. Secondary outcomes included complications, need for an alternative feeding route, hospital stay, readmission, and 90-day mortality. Results: Between May 2017 and October 2023, 406 patients underwent an esophagectomy (312 transthoracic; 94 transhiatal). After matching, 139 patients were included in both the early and late oral feeding groups. Overall complication rates did not significantly differ (84.9% vs. 77.7%; P = 0.124), but the late oral feeding group had less severe complications (48.9% vs. 36.7%; P = 0.039). The late oral feeding group showed lower leakage rates in intrathoracic anastomosis (33.3% vs. 13.3%; P = 0.008), but no differences for cervical anastomosis. The late oral feeding group had a shorter median hospital stay (12 vs. 11 days, P = 0.008). No differences in overall survival rates were found (Kaplan–Meier: P = 0.604, Cox regression: HR: 1.020, 95% CI 0.729–1.427, P = 0.907). Conclusions: Early and late oral feeding showed similar survival rates, but late oral feeding was associated with fewer severe complications, lower anastomotic leakage, and shorter hospital stay. Therefore, despite no survival difference, late oral feeding with jejunal feeding may lead to better postoperative outcomes.